|drug3569||VitalConnect Vital Sign Patch Wiki||0.58|
|drug689||Cardiac MRI Wiki||0.58|
|drug688||Cardiac CT Wiki||0.58|
|D001145||Arrhythmias, Cardiac NIH||0.58|
There are 3 clinical trials
COVID-19 pandemic is a severe viral sepsis characterized by the occurrence of Acute respiratory distress syndrome (ARDS) whose pathophysiology is little described
Description: Caspase-1 activity analyzed in patients in intensive care unit and in patients in standard care unit.Measure: Activation of platelet NLRP3 inflammasome Time: Day 0 During resuscitation (Covid-19 Resuscitation) or hospitalization (Covid-19 No Resuscitation)
Description: Labeling NOD-like receptor protein 3 (NLRP3)/Adaptor protein aptotosis-associated speck-like protein containing a CARD (ASC) analyzed in patients in intensive care unit and in patients in standard care unit.Measure: Activation of platelet NLRP3 inflammasome Time: During Day 0 During resuscitation (Covid-19 Resuscitation) or hospitalization (Covid-19 No Resuscitation)
Respiratory infection with the SARS-CoV2 virus is associated with a major risk of viral pneumonia that can lead to respiratory distress requiring resuscitation. In the most severe forms, it may require a mechanical ventilation or even lead to an acute respiratory distress syndrome with a particularly poor prognosis. The SARS-CoV2 is a single-stranded RNA virus of positive polarity and belongs to the beta genus of Coronaviruses. SARS-CoV2 is responsible for the third epidemic in less than twenty years secondary to a Coronavirus (SARS-CoV then MERS-CoV) and if the mortality associated with it is lower than that of previous strains, particularly MERS-CoV (Middle East Respiratory Syndrome), its spread is considerably bigger. As a result, the number of patients developing respiratory distress that require an invasive mechanical ventilation is high, with prolonged ventilation duration in these situations.
Description: The study aims at evaluating the interests of the biomarkers dosage: endotoxin (LPS) and circulating cytokines (HMGB1 or RAGE) in the prediction of respiratory degradation through a severe form of COVID-19 acquired pneumonia that requires a hospitalization.Measure: Evaluation of the dosage of biomarkers Time: 6 months = study duration
Description: The study will be also focusing on the search for a correlation between the biomarkers by blood samples that will be taken on each hospitalized patients.Measure: Link between the biomarkers Time: 6 months = study duration
Our understanding of the clinical manifestations of COVID-19 is growing on a daily basis and there is evidence that increased age, cardiovascular risk factors and cardiac comorbidity are strongly associated with poor outcomes. Furthermore, myocardial injury occurs and is associated with a much worse outcome and rapid increase in mortality. There have been several reports of myocarditis and heart failure following infection. The mechanisms of myocardial injury and its consequences are not well understood. In an ongoing peer-reviewed and funded study, the investigators are evaluating the use of magnetic resonance imaging (MRI) to characterise and to understand the mechanisms of heart failure and myocarditis. Following strong encouragement by the British Heart Foundation, the investigators now propose to extend this investigation to patients who have recovered from COVID-19 infection to understand the mechanisms of myocardial injury that they have experienced. Using gadolinium and manganese-enhanced MRI combined with Computed tomography coronary angiography (CTCA), the investigators will assess the mechanisms and direct impact of myocardial injury in patients who have recovered from COVID-19 infection. This will help the investigators understand how best to manage individuals who demonstrate evidence of myocardial injury and potentially provide insights that could lead to novel treatment interventions to reduce such injury and improve patient outcomes.
Description: Measure late gadolinium enhancementMeasure: MRI with gadolinium Time: 2 years
Description: Measure T1 values to calculate ECV (%)Measure: Extra-cellular volume (ECV) Time: 2 years
Description: Measure manganese uptakeMeasure: Manganese MRI Time: 2 years
Description: Measure degree of coronary diseaseMeasure: CTCA Time: 2 years
Description: measure troponin profile in patientsMeasure: Cardiac biomarkers Time: 2 years
Description: ECG RhythmMeasure: Electrocardiogram Time: 2 years
Description: ECG ST segmentMeasure: Electrocardiogram Time: 2 years
Description: ECG RateMeasure: Electrocardiogram Time: 2 years
Description: ECG T wave morphologyMeasure: Electrocardiogram Time: 2 years
Description: ECG QT intervalMeasure: Electrocardiogram Time: 2 years
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports